BIOSPECIFICS TECHNOLOGIES CORP Debt Securities, Held-to-maturity, Fair Value
BIOSPECIFICS TECHNOLOGIES CORP had Debt Securities, Held-to-maturity, Fair Value of $118.20 million as of 2020-09-30, per its 10-Q filed 2020-11-09.
Discontinued › Balance Sheet › Assets
us-gaap:HeldToMaturitySecuritiesFairValue · last filed 2020-11-09
- 2020-09-30: Debt Securities, Held-to-maturity, Fair Value $118.20M.
- 2020-06-30: Debt Securities, Held-to-maturity, Fair Value $103.00M.
- 2020-03-31: Debt Securities, Held-to-maturity, Fair Value $94.50M.
- 2019-12-31: Debt Securities, Held-to-maturity, Fair Value $100.80M.
| Period end | Debt Securities, Held-to-maturity, Fair Value |
|---|---|
| 2020-09-30 | $118.20M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $103.00M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $94.50M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $100.80M 10-Q · filed 2020-11-09 |
| 2019-09-30 | $85.60M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $79.50M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $70.50M 10-Q · filed 2019-05-10 |
| 2018-12-31 | $68.80M 10-K · filed 2020-03-16 |
| 2017-12-31 | $57.70M 10-K · filed 2019-04-02 |